At a glance
- Originator Dainippon Sumitomo Pharma
- Class Indoles; Neuroprotectants
- Mechanism of Action Glycine gated NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 06 Feb 2006 No development reported - Preclinical for Neurological disorders (Prevention) in Japan (unspecified route)
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
- 29 Apr 2003 A preclinical study has been added to the Neurological disorders pharmacodynamics section